Table 3.
Evaluation of immunohistochemical markers in the selected studies.
| Author | Marker | Positive IHC Expression (%) | Evaluation Criteria of IHC |
|---|---|---|---|
| Aoyagi, et al. | HER- 2/neu | F: 7/8 (87.5) M: 10/15 (66.6) |
Expression of the antigen was assessed and compared with the reaction in known positive controls semi-quantitatively as follows: <5% of Paget cells positive (score 0); (+) 5–25% of Paget cells positive (score 1); (2+) 26–50% of Paget cells positive (score 2); (3+) >50% of Paget cells positive (score 3). |
| Bianco, et al. | HER-2/neu | 6/15 (40) | Intense staining of tumor cell membranes in the majority of tumor cells was graded as 3+, focal strong membrane staining as 2+, focal low intensity membrane staining as 1+, and granular cytoplasmic staining or no staining of tumor cells as 0. |
| Brummer, et al. |
HER-2/neu | 8/10 (80) | In accordance with the Hercep Test kit guide, HER-2/neu overexpression was assessed as negative for scores of 0 and 1+ and positive for scores of 2+ and 3+. |
| Diaz de Leon, et al. | AR PR ER |
F: 12/23 (52.2) M: 3/5 (60) 0/28 0/28 |
Only nuclear staining with antibodies to steroid receptors was considered specific, and the percentage of cells stained was recorded. |
| Fujimoto, et al. | AR | F: 8/8 (100) M: 16/22 (72.7) |
To roughly measure quantitatively androgen receptor content, a score corresponding to the sum of the percentage of tumor cells stained (0, no staining; 1, less than 25%; 2, 26–50%; 3, 51–75%; 4, 76–100%) and the staining intensity (0, absent; 1, weak; 2, moderate; 3, strong) was established |
| Garganese, et al. | HER-2/neu AR PR ER |
10/41 (24.4) 33/41 (80.5) 9/41 (22) 29/41 (70.7) |
For HER2/neu expression, membrane staining was evaluated according to the ASCO-CAP guidelines described for breast cancer. A tumor showing ER, PR, or AR nuclear staining in a fraction of neoplastic cells ≥ 1% was considered positive. |
| Gatalica, et al. | AR ER |
F: 9/13 (69.2) M: 3/5 (60) F: 2/13 (15.3) M: 2/5 (40) |
AR, ER were analyzed using a ≥ 10% threshold for nuclear positivity. |
| Hanna, et al. | HER-2/neu | 1/20 (5) | Results for HER-2/neu status by immunohistochemistry were reported as follows: positive when at least 10% of the tumor showed moderate/strong complete membrane staining, negative when less than 10% of the tumor showed complete membrane staining or less than 30% showed weak or incomplete membrane staining, and equivocal when ≥ 30% of cells showed diffuse weak staining |
| Hikita, et al. | HER-2/neu | F: 9/11 (81.8) M: 3/6 (50) |
For HER2/neu expression, membrane staining was evaluated according to the ASCO-CAP guidelines |
| Horn, et al. | HER-2/neu ER PR |
8/8 (100) 1/8 (12.5) 1/8 (12.5) |
According to the recommendation for breast cancer, a tumor was counted as positive if a minimum of 10% of the cells showed positive intranuclear staining regardless of staining intensity. For HER-2/neu, only membranous staining results were scored using the system recommended in breast cancer |
| Inoguchi, et al. | AR | F: 1/6 (16.6) M: 14/23 (60.8) |
The stained sections were evaluated microscopically as follows: − = no staining; + = focal deposition in the nest of tumor cells. |
| Kasashima, et al. | AR | F: 12/26 (46) M: 21/32 (65.6) |
Immunopositive labelling of ≥10% among all cells was considered as a positive result |
| Liegl, et al. | HER-2 AR PR ER |
12/23 (52) 18/23 (78) 0/23 1/23 (4) |
For HER2/neu expression, membrane staining was evaluated according to the ASCO-CAP guidelines described for breast cancer. A tumor showing ER, PR, or AR nuclear staining in a fraction of neoplastic cells ≥ 1% was considered positive. |
| Liu, et al. 2018 | HER-2/neu | 5/14 (35.7) | For HER2/neu expression, membrane staining was evaluated according to the ASCO-CAP guidelines |
| Lu, et al. | HER-2/neu | 3/11 (27.2) | For HER2/neu expression, membrane staining was evaluated according to the ASCO-CAP guidelines |
| Masuguchi, et al. | HER-2/neu | F: 7/13 (53.8) M: 4/18 (22.2) |
Grading system: 1+ for slight staining, 3+ for strong staining, and 2+ for staining between 1+ and 3+. |
| Miyamoto, et al. | HER-2/neu | F: 7/14 (50) M: 13/18 (72) |
Only membrane staining was evaluated using the 0 to 3+ scale illustrated in the HercepTest scoring guideline (0 for no staining or membrane staining in less than 30% of the cells; 1+ for partial, weak staining of the cell membrane in 30% of the cells; 2+ for moderate staining of the complete cell membrane in 30% of the cells; 3+ for intense staining of the complete membrane in.30% of the cells |
| Morbeck, et al. | HER-2/neu | 6/11 (54.5) | For HER2/neu expression, membrane staining was evaluated according to the ASCO-CAP guidelines |
| Ogawa, et al. | HER-2/neu | F: 1/5 (20) M: 6/29 (20.6) |
3+: more than 10% of tumor cells show strong complete membrane staining; 2+: more than 10% of tumor cells show weak or moderate and complete membrane staining; 1+: positively stained cells are less than 10% or show only faint staining, although more than 10% of cells are positive; 0, no staining. According to the recommendation of the US Food and Drug Administration, 3+ and 2+ were recorded as overexpressed and 1+ and 0 as non-overexpressed. |
| Plaza, et al. | HER-2/neu | F: 14/33 (42.4) M: 1/14 (7) |
no staining or membrane staining in less than 10% of the cells; 1+ for partial, weak staining of the cell membrane in. 10% of the cells; 2+ for moderate staining of the complete cell membrane in 10% of the cells; 3+ for intense staining of the complete membrane in 10% of the cells). Overexpression was assessed as positive for scores 2 and 3+ and negative for scores 0 and 1+. |
| Reich, et al. | HER-2/neu | 4/6 (100) | For HER2/neu expression, membrane staining was evaluated according to the ASCO-CAP guidelines |
| Richter, et al. | HER-2/neu | 19/33 (57.5) | Staining was considered to be 0 for no staining, 1+ with less than 10% positively stained cells or cells that showed only faint staining, although more than 10% of cells were positive, 2+ when they showed more than 10% weak or moderate and complete membrane staining, and 3+ when more than 10% of tumor cells showed strong complete membrane staining.21 According to the standard guideline used for breast cancer, 2+ and 3+ tumors were recorded as ‘overexpressed’, 0 and 1+ tumors as ‘non-overexpressed’ |
| Sekiguchi, et al. | HER-2/neu | F: 2/2 (100) M: 2/2 (100) |
For HER2/neu expression, membrane staining was evaluated according to the ASCO-CAP guidelines |
| Tanaka, et al. | HER-2/neu | F: 2/4 (50) M: 4/22 (18) |
3+, strong, complete membrane staining in more than 30% of the malignant cells; 2+, weak to moderate complete membrane staining in more than 10% of the malignant cells or strong, complete membrane staining in more than 10–30% of the malignant cells; 1+, weak to moderate incomplete membrane staining; 0, fewer than 10% of membrane staining or no membrane staining. Those cases scored 0 and 1+ were defined as negative. Cases scored 2+ and 3+ were defined as equivocal and overexpression, respectively |
| Tanaka, et al. | HER-2/neu | F: 5/35 (14.2) M: 7/69 (10) |
3+, strong, complete membrane staining in more than 30% of the malignant cells; 2+, weak to moderate complete membrane staining in more than 10% of the malignant cells or strong, complete membrane staining in more than 10–30% of the malignant cells; 1+, weak to moderate incomplete membrane staining; 0, fewer than 10% of membrane staining or no membrane staining. Those cases scored 0 and 1+ were defined as negative. Cases scored 2+ and 3+ were defined as equivocal and overexpression, respectively |
| Tanskanen, et al. | HER-2/neu | F: 12/23 (52) M: 4/9 (44.44) |
For HER2/neu expression, membrane staining was evaluated according to the ASCO-CAP guidelines |
| Zhang, et al. | HER-2/neu | 1/2 (50) | For HER2/neu expression, membrane staining was evaluated according to the ASCO-CAP guidelines |